Literature DB >> 788888

Extranodal presentation of non-Hodgkin's lymphomas in the testis.

P V Woolley, C K Osborne, J A Levi, P H Wiernik, G P Canellos.   

Abstract

The clinical and pathologic features of six patients, each of whom exhibited a testicular mass as the first sign of a lymphoma, are discussed. All underwent extensive staging procedures. Retroperitoneal lymph nodes and bone were frequent sites of extratesticular involvement early in the disease. Later widespread dissemination to multiple organs occurred in five of six patients. CNS involvement was a prominent feature of advancing disease. One patient was apparently cured by orchiectomy alone. Although the others exhibited partial responses to chemotherapy and radiation, the disease was fatal to all of them within a year of orchiectomy. Early, aggressive systemic treatment of these patients appears necessary.

Entities:  

Mesh:

Year:  1976        PMID: 788888     DOI: 10.1002/1097-0142(197608)38:2<1026::aid-cncr2820380256>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Primary testicular and intraocular lymphomas: two case reports and a review of the literature.

Authors:  Dana J Wallace; Chandra R Altemare; De Fen Shen; Marc D deSmet; Ronald R Buggage; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 6.048

2.  Diagnosis of systemic metastatic retinal lymphoma.

Authors:  Xiaoguang Cao; Defen Shen; David G Callanan; Manabu Mochizuki; Chi-Chao Chan
Journal:  Acta Ophthalmol       Date:  2011-03       Impact factor: 3.761

3.  Pathological stage ie lymphoma of the testis treated by local surgery alone.

Authors:  M W Kissin; A E Kark
Journal:  Postgrad Med J       Date:  1982-05       Impact factor: 2.401

4.  The need for prophylactic treatment to the central nervous system in patients with aggressive non-Hodgkin's lymphoma.

Authors:  C J Hawkey; P J Toghill
Journal:  Postgrad Med J       Date:  1983-05       Impact factor: 2.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.